GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    American Society of Clinical Oncology (ASCO) ; 1996
    In:  Journal of Clinical Oncology Vol. 14, No. 10 ( 1996-10), p. 2638-2645
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 14, No. 10 ( 1996-10), p. 2638-2645
    Abstract: To identify prognostic variables for response and survival in male patients with relapsed or refractory germ cell tumors treated with high-dose chemotherapy (HDCT) and hematopoietic progenitor cell support. PATIENTS AND METHODS Three hundred ten patients treated with HDCT at four centers in the United States and Europe were retrospectively evaluated. Univariate and multivariate analysis of patient, disease, and treatment characteristics were used for comparisons of response rates and failure-free survival (FFS). RESULTS The actuarial FFS rate was 32% at 1, 30% at 2, and 29% at 3 years. Multivariate analysis identified progressive disease before HDCT, mediastinal nonseminomatous primary tumor, refractory or absolute refractory disease to conventional-dose cisplatin, and human chorionic gonadotropin (HCG) levels greater than 1,000 U/L before HDCT as independent adverse prognostic variables for FFS after HDCT. These variables were used to identify patients with good, intermediate, and poor prognoses. In the good-risk category, the predicted FFS rate at 2 years was 51%, compared with 27% and 5% in the intermediate-risk and poor-risk categories (P 〈 .001). The increased risk for treatment failure was due to both a significantly lower rate of favorable responses and a significantly higher rate of relapses. Within the prognostic categories, the particular HDCT regimen or higher dosages of carboplatin or etoposide did not have a significant influence on treatment outcome. CONCLUSION Prognostic variables for treatment response after HDCT can be identified. The proposed prognostic model might help to optimize the use of HDCT in germ cell tumors and warrants validation in future trials.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 1996
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: British Journal of Cancer, Springer Science and Business Media LLC, Vol. 107, No. 7 ( 2012-9), p. 1025-1030
    Type of Medium: Online Resource
    ISSN: 0007-0920 , 1532-1827
    RVK:
    RVK:
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2012
    detail.hit.zdb_id: 2002452-6
    detail.hit.zdb_id: 80075-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2016
    In:  Cancer Research Vol. 76, No. 4_Supplement ( 2016-02-15), p. P2-09-16-P2-09-16
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 76, No. 4_Supplement ( 2016-02-15), p. P2-09-16-P2-09-16
    Abstract: Breast cancer is the most frequent female cancer with 48 800 new cases each year in France. A French national screening program in women without genetic risk factors has been initiated in 2004. Women with BRCA 1 or 2 mutations are included in surveillance programs. Women without such mutations can be assessed for breast cancer risk using risk prediction models. The aim of this study is to compare the performance of three breast cancer risk prediction models: GAIL2, BODICEA and IBIS in a population of patients (pts) who developed breast cancer. Patients and Methods: The GAIL1 model was performed to 188 pts at high risk of breast cancer according to their family history and who developed breast cancer. Personal and familial data was regenerated at the day before the diagnosis of breast cancer and the three models were applied. From this population, 60 pts were selected: for whom all information necessary to use the 3 models was available and for whom the GAIL1 model provided sufficient variability in the relative risk of breast cancer. The GAIL2 model takes into account individual risk factors: age, menarches, parity, age at first birth, history of breast biopsy, atypical hyperplasia or in situ lobular carcinoma. The BODICEA model considers age and familial risk factors: number of related affected by breast ovarian, prostate and pancreas cancer and age at diagnosis. Both personal and familial risk factors are used for the IBIS model. We estimated lifetime breast cancer risk for each patient with the three models from the available software packages. We assessed Pearson's correlation coefficient between the three models. Results Median (range) age was 45 years (25-74). Risk prediction could not be evalauted by the GAIL2 model for 14 pts since they were less than 35 years of age. Lifetime breast cancer risk was 16.1% (4.4-38.7) for GAIL2, 11.6% (2.2-39.5) for BODICEA and 16.5% (3.5-36.3) for IBIS. Pearson's correlation coefficient between BODICEA and GAIL2, IBIS and GAIL2 and between BODICEA and IBIS were 0.36, 0.38 and 0.69 respectively. In most cases, IBIS risk predictions were higher than GAIL2's which were higher than BODICEA's as soon as lifetime risk was at least 20%. When the three models were applicable (46pts), IBIS estimated a higher risk in 31 cases (67%) versus 10 for GAIL2 (21.74%) and 5 for BODICEA (10.86%). The median (range) time for use of the tools per patient was 30 seconds (16-80) for GAIL2, 588 (198-1804) for BODICEA and 86 (46-135) for IBIS. Discussion Results in this selected population of pts who developed breast cancer show that IBIS seems to be the better performer to predict breast cancer risk:. Results are obtained faster and the risk predictions provide higher estimates. The GAIL2 model is quick and easy to use but with a limited number of items. Conversely, BODICEA requires a very large number of items, not always available, and does not consider incomplete data. In conclusion, IBIS model seems to be the most suitable for practical use in the evaluation of breast cancer risk. Citation Format: Mailliez A, Kramar A, Peyrat J-P, Revillion F, Bonneterre J. Comparison of prediction models of breast cancer in high risk populations?. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-09-16.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2016
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 24_Supplement ( 2012-12-15), p. OT1-2-02-OT1-2-02
    Abstract: Introuction: The six worldwilde ongoing APBI phase III trials are characterized by a significant heterogeneity regarding inclusion criteria and stratifications. One non-inferiority trial (SHARE) is currently ongoing in France. SHARE Trial design: SHARE will randomize 2800 patients in 3 arms: standard (Arm A; 6.5 weeks) versus hypofractionated (Arm B; 3 weeks) versus APBI (Arm C; 1 week) using only 3D conformal radiotherapy (3D CRT). In this trial high quality and homogeneous criteria in surgery, pathology and RT for the 3 arms is planed. Primary objective: To estimate and compare the rates of local recurrences between the experimental and control arms. Inclusion criteria Post menopausal women aged ≥ 50y (stratification: & lt; 70 yrs vs ≥ 70 yrs) Menopausal status confirmed since ≥ 12 months (Clinically and/or biologically) No previous ipsilateral breast and/or mediastinal irradiation Pathologic confirmation of invasive carcinoma (all types of invasive carcinomas) Unifocal tumor confirmed on the pathologic specimen Pathologic tumor size of the carcinoma ≤ 2cm (including the in situ component) All pathologic grades (stratification: HER2/triple negative vs others) Clear lateral margins confirmed on the final pathology report. The minimal size from the invasive and in situ disease should be 2 mm (≥ 2mm) pN0 (i+/−) (stratification: pN0 vs pN(i+)) Chemotherapy and trastuzumab are not allowed - RT should be started ≥ 4weeks and ≤ 12 weeks after surgery (including the date of second excision for close or involved margins) Clips in the tumor bed placed during surgery (4 to 5 clips) Treatment Arm A 3D CRT should be started within 12 weeks after the last surgery. A total of 50 Gy is delivered in 25 fractions, one fraction of 2 Gy per day, 5 days a week. In this arm, the boost of 10 to 16 Gy is delivered in 5 to 8 fractions. Dose prescription (arm B) The main point is that in both schedules the total dose is delivered in 3 weeks: – The Canadian schedule described by Whelan et al. delivers 42.5 Gy in 16 fractions (2.65Gy/fraction, 5 fractions/week).– The UK schedule, reported in START B trial delivers 40 Gy in 15 fractions (2.66 Gy/ fraction, 5 fractions/week). Nodal and boost RT is not allowed. Arm C 3D CRT should be started within 12 weeks after the last surgery. Intensity modulated RT (IMRT) and brachytherpayare not allowed. A total dose of 40 Gy in 10 fractions over 1 week (4Gy per fraction twice a day with minimal delay of 6h). Conclusion: In summary, the French trial will allow: – Selected patients according to age and low risk of local recurrence parameters.– To evaluate in a subgroup of patients (4 to 5 centers), the impact of magnetic resonance imaging (MRI) for patient selection and the rate of occult disease (multifocality) not detected by standard imaging evaluation which is considered as an exclusion criteria.– To determine APBI parameters adapted to the surgical procedure in the tumor bed remodeling setting.– To determine homogeneous criteria for the surgical procedure, minimal requirements and optimal criteria that have to be mentioned in the final pathology report in all 3 arms of the study.– To test hypofractionation using 3 weeks-schedules as compared to APBI Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr OT1-2-02.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Oncology Reports, Spandidos Publications, ( 1998-09-01)
    Type of Medium: Online Resource
    ISSN: 1021-335X , 1791-2431
    Language: Unknown
    Publisher: Spandidos Publications
    Publication Date: 1998
    detail.hit.zdb_id: 1222484-4
    detail.hit.zdb_id: 2120548-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2012
    In:  Cancer Research Vol. 72, No. 24_Supplement ( 2012-12-15), p. S5-3-S5-3
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 24_Supplement ( 2012-12-15), p. S5-3-S5-3
    Abstract: Background: Since 2005, One year trastuzumab (T) treatment has been providing survival benefit to patients with early breast cancer and HER2 overexpression. However, the optimal duration of T has been debatable due to concerns for cardiac toxicity and results from the FinHer trial which showed that 9 weeks of T provided a similar magnitude of benefit than the 1-year treatment. The French National Cancer Institute (INCa) initiated an academic randomised non-inferiority trial aiming to compare a shorter T exposure of 6 months versus the standard 12 months. This trial, named PHARE for ‘Protocol for Herceptin® as Adjuvant therapy with Reduced Exposure’ [NCT00381901] was approved byan independent ethics committee with regularly planned IDMC meetings. Patients and methods: Patients with HER2 + early breast cancer who received at least 4 cycles of (neo)-adjuvant chemotherapy were eligible. Randomization 1:1 using a minimisation algorithm was stratified on concomitant or sequential T administration with chemotherapy, oestrogen receptors (ER) status and center. The primary objective was to compare disease free survival (DFS). Overall survival (OS) and cardiac toxicity were investigated as secondary aims. An absolute loss of 2% in DFS in the experimental arm was defined as the non-inferiority margin (1.15 in relative terms) and required 3400 patients with alpha=0.05 and 80% power. Results: Between 5/2006 and 7/2010, 3382 patients were randomized to 6 or 12 months of T following the IDMC recommendation for accrual interruption and extended follow-up. Disease and treatment characteristics were well balanced between the 2 arms: median age 55 years (range 21–86), median tumour size 20 mm (0–270), node involvement 45%, SBR grade III 56%, ER positive 58%, radiotherapy 88%; concomitant T administration 58%, anthracyclin and taxane containing chemotherapy 73%. The data-base was locked on July 30th, 2012. The 95% HR confidence interval was ranged between 1.09–1.66 for DFS between the 2 arms and it included the pre-specified non-inferiority margins of 1.15. Thus the results were inconclusive regarding the non-inferiority (p = 0.14). A subset analysis based on stratification factors will be presented at SABCS. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr S5-3.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    Springer Science and Business Media LLC ; 2004
    In:  British Journal of Cancer Vol. 91, No. 7 ( 2004-10), p. 1251-1260
    In: British Journal of Cancer, Springer Science and Business Media LLC, Vol. 91, No. 7 ( 2004-10), p. 1251-1260
    Type of Medium: Online Resource
    ISSN: 0007-0920 , 1532-1827
    RVK:
    RVK:
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2004
    detail.hit.zdb_id: 2002452-6
    detail.hit.zdb_id: 80075-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 76, No. 4_Supplement ( 2016-02-15), p. P3-12-18-P3-12-18
    Abstract: Purpose/Objective(s): We and others showed in retrospective and monocentric studies that radiation-induced CD8-lymphocyte apoptosis (RILA) can significantly predict differences in late toxicity between individuals and can be used as a rapid screening for potential hyper-reactive patients to radiation therapy (RT). We present here the clinical results of the prospective multicenter French trial (NCT00893035) evaluating the predictive role of RILA as a predictor of late effects after RT. Materials/Methods: A total of 502 consenting breast-cancer patients (pts) treated by conservative surgery and adjuvant RT were included by 10 French centers. Lymphocytes apoptosis was assessed before RT by associated condensation of DNA. The incidence of late toxicities was obtained using CTCAEv3.0 grading scale. Complication-free survival (CFS) and complication-relapse-free survival (CRFS) curves were estimated by the Kaplan-Meier method. The log-rank test was used to identify significant categorical variables for each of the survival curves. Cox model was used for multivariate analysis. Results: Four hundred and fifty-four pts (90.4%) were included in the final analysis (clinical, biological and dosimetric data available). One hundred and eight pts (24%) received both whole breast (WB) and nodal irradiation (NI). A boost dose of 10-16 Gy was given in 448 pts (99%). Adjuvant hormonotherapy (tamoxifen or aromatase inhibitor) was delivered to 346 pts (76%). Three categories of absolute change in the percent CD8 cells in apoptosis before and after exposure to 8-Gy in vitro RT were constructed around the 33 percent quantiles, & lt;12%, 12-20%, and & gt;20%. In a median follow-up period of 38.5 months, grade 2 and 3 late fibrosis was observed in 54 (12%) and 3 (0.7%) pts, respectively. A decreased percentage of grade 2 or more late toxicity was observed for increasing values of CD8 apoptosis (p=0.001). No grade 3 late toxicity was observed for patients with RILA ≥12%. The 3-year CFS rates were significantly lower for patients with low levels of CD8 radiation-induced apoptosis, 79% (95% confidence interval [CI]: 72–85%), 90% (95% CI: 84–94%), and 93% (95% CI: 87–96%) for CD8 & lt;12%, 12–20%, and & gt;20%, respectively (p=0.001). Similar results were observed for the CRFS rates (p & lt;0.001). In multivariate analyses, prognostic factors for CFS were RILA & lt;12% (p=0.001), smoking history (p & lt;0.001), and adjuvant hormonal treatment (p=0.008). Negative predictive value for grade 2 or more toxicity was equal to 83% for CD8 & gt;20% and positive predictive value was equal to 22% for CD8 & lt;12% where the overall prevalence of grade 2 or more late side effects was estimated at 14%. Conclusion: RILA significantly predicts differences in radiation-induced late toxicity between individuals. This study validates the use of RILA as a rapid screening for potential hyper-reactive pts to radiotherapy. Citation Format: Hennequin C, Azria D, Riou O, Castan F, Coelho M, Nguyen TD, Peignaux K, Lemanski C, Lagrange J-L, Kirova Y, Lartigau E, Belkacemi Y, Bourgier C, Noel G, Clippe S, Mornex F, Kramar A, Pèlegrin A, Ozsahin M. Radiation-induced CD8 T-lymphocyte apoptosis as a predictor of late toxicity after radiotherapy: Results of the prospective multicenter French trial. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-12-18.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2016
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: British Journal of Cancer, Springer Science and Business Media LLC, Vol. 89, No. 10 ( 2003-11), p. 1987-1994
    Type of Medium: Online Resource
    ISSN: 0007-0920 , 1532-1827
    RVK:
    RVK:
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2003
    detail.hit.zdb_id: 2002452-6
    detail.hit.zdb_id: 80075-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    Elsevier BV ; 2004
    In:  European Journal of Cancer Vol. 40, No. 8 ( 2004-05), p. 1244-1249
    In: European Journal of Cancer, Elsevier BV, Vol. 40, No. 8 ( 2004-05), p. 1244-1249
    Type of Medium: Online Resource
    ISSN: 0959-8049
    RVK:
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2004
    detail.hit.zdb_id: 1120460-6
    detail.hit.zdb_id: 1468190-0
    detail.hit.zdb_id: 82061-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...